Patents Assigned to NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS
  • INDIRUBIN DERIVATIVES, AND USES THEREOF
    Publication number: 20230174483
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 8, 2023
    Applicants: CITY OF HOPE, THE NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
    Inventors: Sangkil NAM, Richard JOVE, Leandros SKALTSOUNIS
  • Indirubin derivatives, and uses thereof
    Patent number: 11524937
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 13, 2022
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • 5-bromo-indirubins
    Patent number: 11306072
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 19, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Thioindirubins
    Patent number: 11213510
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: January 4, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, David Horne, Ravi Salgia, Alexios Leandros Skaltsounis, Nicolas Gaboriaud-Kolar, Panagiotis Gerolymatos, Nikolaos Lougiakis
  • INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF
    Publication number: 20210393548
    Abstract: The present disclosure provides inhibitors of bunyavirus of the formula: wherein the variables are defined herein.
    Type: Application
    Filed: May 12, 2021
    Publication date: December 23, 2021
    Applicants: Saint Louis University, Research Foundation of The City University of New York, National and Kapodistrian University of Athens
    Inventors: John Edwin TAVIS, Grigoris ZOIDIS, Amelia PINTO, James BRIEN, Ryan MURELLI
  • Pyridopyrazine compounds and uses thereof
    Patent number: 11117894
    Abstract: Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 14, 2021
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, David Horne, Ravi Salgia, Alexios-Leandros Skaltsounis, Nikolaos Lougiakis, Nicole Pouli, Panagiotis Marakos
  • Indirubin derivatives, and uses thereof
    Patent number: 10435367
    Abstract: Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 8, 2019
    Assignees: City of Hope, The National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, Richard Jove, Leandros Skaltsounis
  • AUTOTAXIN INHIBITORS AND USES THEREOF
    Publication number: 20180141965
    Abstract: Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases).
    Type: Application
    Filed: May 18, 2016
    Publication date: May 24, 2018
    Applicant: NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
    Inventor: GEORGE KOKOTOS
  • ACCELERATION OF WOUND HEALING BY GROWTH HORMONE RELEASING HORMONE AND ITS AGONISTS
    Publication number: 20130261058
    Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.
    Type: Application
    Filed: September 16, 2011
    Publication date: October 3, 2013
    Applicants: University of Miami, U.S. Department of Veterans Affairs, National and Kapodistrian University of Athens
    Inventors: Andrew V. Schally, Hippokratis Kiaris, Norman L. Block
  • Process for the Manufacture of Saturated Fatty Acid Esters
    Publication number: 20100234625
    Abstract: Disclosed is a process for the manufacture of saturated fatty acid esters by subjecting unsaturated fatty acid esters to hydrogenation in the presence of a catalyst suitable for catalysing the saturation of double bonds in the esters, which is characterised in that said catalyst represents a homogenous complex of a Group VIII metal and a sulfonated phosphite as the polar ionic ligand.
    Type: Application
    Filed: June 14, 2008
    Publication date: September 16, 2010
    Applicants: COGNIS IP MANAGEMENT GMBH, NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS
    Inventors: Georgios Papadogianakis, Achilleas Bouriazos, Angeliki Tsichla, Christiana Vasiliou